PaulH.JohnsonMD

PubMed

• Phage display screening of epithelial cell monolayers treated with EGTA: identification of peptide FDFWITP that modulates tight junction activity.
  Herman, R.E., Makienko, E.G., Prieve, M.G., Fuller, M., Houston, M.E., Johnson, P.H.> ;J Biomol Screen. 2007 Dec
• The Trp cage motif as a scaffold for the display of a randomized peptide library on bacteriophage T7.
  Herman, R.E., Badders, D., Fuller, M., Makienko, E.G., Houston, M.E., Quay, S.C., Johnson, P.H.> ;J Biol Chem. 2007 Mar 30
• Selective inhibitors of bacterial DNA adenine methyltransferases.
  Mashhoon, N., Pruss, C., Carroll, M., Johnson, P.H., Reich, N.O.> ;J Biomol Screen. 2006 Aug
• Therapeutic utility of a novel tight junction modulating peptide for enhancing intranasal drug delivery.
  Chen, S., Eiting, K., Cui, K., Leonard, A.K., Morris, D., Li, C., Farber, K., Sileno, A.P., Houston, M.E., Johnson, P.H., Quay, S.C., Costantino, H.R.> ;J Pharm Sci. 2006 Jun
• Multiplex gene expression analysis for high-throughput drug discovery: screening and analysis of compounds affecting genes overexpressed in cancer cells.
  Johnson, P.H., Walker, R.P., Jones, S.W., Stephens, K., Meurer, J., Zajchowski, D.A., Luke, M.M., Eeckman, F., Tan, Y., Wong, L., Parry, G., Morgan, T.K., McCarrick, M...> ;Mol Cancer Ther. 2002 Dec
• Connective tissue activation. XXXIV: Effects of proteolytic processing on the biologic activities of CTAP-III.
  Castor, C. W., Walz, D. A., Johnson, P. H., Hossler, P. A., Smith, E. M., Bignall, M. C., Aaron, B. P., Underhill, P., Lazar, J. M., Hudson, D. H.> ;J Lab Clin Med. 1990 Oct
• Identification and characterization of PF4varl, a human gene variant of platelet factor 4.
  Green, C. J., Charles, R. S., Edwards, B. F., Johnson, P. H.> ;Mol Cell Biol. 1989 Apr
• Expression of synthetic genes encoding fused proteins under tight control of modified regulatory regions of the colicin operon.
  Waleh, N. S., Sohel, I., Lazar, J. B., Hudson, D. V., Sze, P., Underhill, P. A., Johnson, P. H.> ;Gene. 1992 Aug 1
• The crystal structure of recombinant human neutrophil-activating peptide-2 (M6L) at 1.9-A resolution.
  Malkowski, M. G., Wu, J. Y., Lazar, J. B., Johnson, P. H., Edwards, B. F.> ;J Biol Chem. 1995 Mar 31
• Inhibition of human metapneumovirus replication by small interfering RNA.
  Deffrasnes, C., Cavanagh, M. H., Goyette, N., Cui, K., Ge, Q., Seth, S., Templin, M. V., Quay, S. C., Johnson, P. H., Boivin, G.> ;Antivir Ther (Lond). 2008 Oct 09
• Identification of AKT-regulated genes in inducible MERAkt cells.
  Kuhn, I., Bartholdi, M. F., Salamon, H., Feldman, R. I., Roth, R. A., Johnson, P. H.> ;Physiol Genomics. 2001 Dec 21
• Intranasal administration of acetylcholinesterase inhibitors.
  Costantino, H. R., Leonard, A. K., Brandt, G., Johnson, P. H., Quay, S. C.> ;BMC Neurosci. 2009 Jan 06
• Discovery of tight junction modulators: significance for drug development and delivery.
  Johnson, P. H., Frank, D., Costantino, H. R.> ;Drug Discov Today. 2008 Mar
• Identification of gene expression profiles that predict the aggressive behavior of breast cancer cells.
  Zajchowski, D. A., Bartholdi, M. F., Gong, Y., Webster, L., Liu, H. L., Munishkin, A., Beauheim, C., Harvey, S., Ethier, S. P., Johnson, P. H.> ;Cancer Res. 2001 Jul 1
• Advances in nasal drug delivery through tight junction technology.
  Johnson, P. H., Quay, S. C.> ;Expert Opin Drug Deliv. 2005 Mar
• Intranasal delivery: physicochemical and therapeutic aspects.
  Costantino, H. R., Illum, L., Brandt, G., Johnson, P. H., Quay, S. C.> ;Int J Pharm. 2007 Jun 7
• Join now to see all